Bruker Announces Fourth Quarter 2021 Dividend


2021-11-15 22:00:08 BioSpace


Plans to Increase 2022 Annual Dividend from $0.16 to $0.20 per share BILLERICA, Mass.--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) today announced that its Board of Directors has approved payment of a quarterly cash dividend in the amount of $0.04 per share on the Company’s common stock. The dividend will be paid on December 17, 2021 to stockholders of record as of December 1, 2021. In addition, the Board approved the Company’s plan to increase its annual cash dividend from $0.16 to $0.20, payable quarterly beginning in March 2022, subject to quarterly Board approval. About Bruker Corporation (Nasdaq: BRKR) Bruker is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker’s high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity and customer success in life science molecular and cell biology research, in applied and pharma applications, in microscopy and nanoanalysis, as well as in industrial applications. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit: Forward Looking Statements Any statements contained in this press release which do not describe historical facts may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding expected quarterly cash dividends in 2022. Any forward-looking statements contained herein are based on current expectations, but are subject to risks and uncertainties that could cause actual results to differ materially from those indicated, including, but not limited to, those risk factors discussed from time to time in our filings with the Securities and Exchange Commission, or SEC. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our annual report on Form 10-K for the year ended December 31, 2020, as may be updated by our quarterly reports on Form 10-Q. We expressly disclaim any intent or obligation to update these forward-looking statements other than as required by law. View source version on Investor Relations Bruker Corporation T: +1 (978) 663–3660, ext. 1479 E: Source: Bruker Corporation View this news release online at:
计划将2022年年度股息从每股0.16美元增加到0.20美元 布鲁克公司(纳斯达克股票代码:BRKR)今天宣布,其董事会已经批准支付该公司普通股每股0.04美元的季度现金股利。股息将于2021年12月17日支付给截至2021年12月1日为止的记录在案的股东。 此外,董事会批准本公司计划将年度现金股息由0.16美元增加至0.20美元,自2022年3月起按季度支付,但须待季度董事会批准。 关于布鲁克公司(纳斯达克代码:BRKR) 布鲁克使科学家能够取得突破性的发现,并开发新的应用,提高人类生活质量。布鲁克的高性能科学仪器和高价值的分析和诊断解决方案使科学家能够在分子、细胞和微观层面探索生命和材料。通过与客户的密切合作,Bruker在生命科学分子和细胞生物学研究、应用和制药应用、显微镜和纳米分析以及工业应用领域实现创新、提高生产力和客户成功。布鲁克在临床前影像学、临床表现学研究、蛋白质组学和多组学、空间和单细胞生物学、功能结构和凝析生物学以及临床微生物学和分子诊断学方面提供差异化、高价值的生命科学和诊断系统和解决方案。欲了解更多信息,请访问。 前瞻性陈述 本新闻稿中包含的任何不描述历史事实的陈述都可能构成1933年《证券法》(经修订)第27A条和1934年《证券交易法》(经修订)第21E条含义范围内的前瞻性陈述,包括关于2022年预期季度现金股利的陈述。本文所载的任何前瞻性陈述都是基于当前的预期,但会受到风险和不确定性的影响,这些风险和不确定性可能导致实际结果与所表明的结果有重大差异,包括但不限于我们在向证券交易委员会提交的文件中不时讨论的风险因素。我们向证交会提交的文件包括但不限于我们截至2020年12月31日止年度的表格10-K年度报告(表格10-Q季度报告可能会更新)中更详细地确定和描述了这些和其他因素。除法律要求外,我们明确否认更新这些前瞻性陈述的任何意图或义务。 在businesswire.com查看源代码版本: 投资者关系 布鲁克公司 T:+1(978)663-3660,电话分机。1479 资料来源:布鲁克公司 在网上查看此新闻稿: